Abstract |
The Gynecologic Oncology Group performed a Phase II study to determine the response rate of pyrazoloacridine (PZA) in patients with platinum-resistant ovarian cancer. PZA was administered at a dose of 750 mg/m2 intravenously over 3 hours every 3 weeks. Among 24 evaluable patients, there was 1 (4.2%) complete and 1 (4.2%) partial response. The major toxicities were hematologic. With the dose and schedule used, PZA had only modest activity in this population.
|
Authors | Steven C Plaxe, John A Blessing, Mark A Morgan, John Carlson, Gynecologic Oncology Group |
Journal | American journal of clinical oncology
(Am J Clin Oncol)
Vol. 25
Issue 1
Pg. 45-7
(Feb 2002)
ISSN: 0277-3732 [Print] United States |
PMID | 11823695
(Publication Type: Clinical Trial, Clinical Trial, Phase II, Journal Article, Multicenter Study, Research Support, U.S. Gov't, P.H.S.)
|
Chemical References |
- Acridines
- Antineoplastic Agents
- Pyrazoles
- Carboplatin
- NSC 366140
- Cisplatin
|
Topics |
- Acridines
(administration & dosage, therapeutic use)
- Adult
- Aged
- Antineoplastic Agents
(administration & dosage, therapeutic use)
- Carboplatin
(therapeutic use)
- Cisplatin
(therapeutic use)
- Drug Resistance, Neoplasm
- Female
- Humans
- Middle Aged
- Ovarian Neoplasms
(drug therapy)
- Pyrazoles
(administration & dosage, therapeutic use)
|